Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Exelixis and Bristol-Myers Squibb to co-develop new cancer drug
Under the terms of the collaboration agreement between the two companies, which became effective in January 2007, the selection of XL413 by Bristol-Myers Squibb entitles Exelixis to a
Under the terms of the collaboration agreement between the two companies, which became effective in January 2007, the selection of XL413 by Bristol-Myers Squibb entitles Exelixis to a
Under the terms of the option agreement, Cephalon will pay ImmuPharma a $15 million upfront option payment. If the Phase IIb studies are successful and if the option
GlaxoSmithKline (GSK) will be providing certain distribution support services for an interim period. The agreement also marks the start of a strategic relationship with GSK whereby Paladin Labs
The product will be sold in the US by Ovation Pharmaceuticals, a biopharmaceutical company, which will market Xenazine to US specialists through its 48-person sales force. The launch
Under the agreement, Auxilium will be responsible for manufacturing and supplying Testim to Ferring, while Ferring will be responsible for all regulatory, sales, marketing and distribution activities in
This follows Artes Medical’s disclosure that it has initiated a significant workforce reduction, and that it has not been able to address its anticipated liquidity issues. Anika said
Under the terms of the memorandum of understanding (MoU), Akorn will be responsible for the development, regulatory filings, marketing and distribution of the premix product line. Bioluz will
This randomized, multi-center, open-label study will be conducted among 228 adult patients with intermediate-1, intermediate-2 and high-risk myelodysplastic syndromes (MDS). Patients will be randomized on a 1:1 ratio
Most recently, Mr Pfreundschuh was executive director of business development and licensing at AstraZeneca, where he led finance and negotiations in support of new business development opportunities for
The collaboration will focus on amyotrophic lateral sclerosis (ALS) with Shinn-Zong Lin as principle investigator. Richard Garr, president and CEO of Neuralstem, said: “We are pleased to have